HBM Healthcare Investments AG Stock price
Equities
HBMN
CH0012627250
Investment Management & Fund Operators
Delayed Swiss Exchange 11:30:20 2023-09-22 am EDT |
|
5-day change | 1st Jan Change | |
175.40 CHF | -1.90% | -3.20% | -12.74% |
Jul. 21 | HBM Healthcare Investments AG Reports Earnings Results for the First Quarter Ended June 30, 2023 | CI |
Jul. 21 | HBM Healthcare Investments' Ficsal Q1 NAV Per Share Declines | MT |
Sales 2024 * | -42 M -47 M | Sales 2025 * | 46 M 51 M | Capitalization | 1 220 M 1 344 M |
---|---|---|---|---|---|
Net income 2024 * | -71 M -78 M | Net income 2025 * | 18 M 20 M | EV / Sales 2024 * | -28,0x |
Net cash position 2024 * | 32 M 35 M | Net cash position 2025 * | 44 M 48 M | EV / Sales 2025 * | 25,5x |
P/E ratio 2024 * | -16,9x | P/E ratio 2025 * | 72,5x | Employees | - |
Yield 2024 * | 4,28% | Yield 2025 * | 3,95% | Free-Float | 82.84% |
More Fundamentals
* Assessed data
More news
More news
1 day | -1.90% | ||
1 week | -3.20% | ||
Current month | -1.68% | ||
1 month | -3.09% | ||
3 months | -10.05% | ||
6 months | -13.38% | ||
Current year | -12.74% |
1 week
175.00
181.40

1 month
173.60
188.00

Current year
173.60
232.50

1 year
173.60
243.00

3 years
173.60
367.00

5 years
140.00
367.00

10 years
62.40
367.00

Managers | Title | Age | Since |
---|---|---|---|
Andreas Wicki
CEO | Chief Executive Officer | 64 | 2012 |
Erwin Troxler
DFI | Director of Finance/CFO | 53 | 2011 |
Benedikt Suter
SEC | Corporate Secretary | 59 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mario Giuliani
BRD | Director/Board Member | 51 | 2011 |
Chairman | 67 | 2009 | |
Stella Xu
BRD | Director/Board Member | 52 | - |
Date | Price | Change | Volume |
---|---|---|---|
23-09-22 | 175.40 | -1.90% | 3,713 |
23-09-21 | 178.80 | -0.45% | 2,001 |
23-09-20 | 179.60 | +1.70% | 3,969 |
23-09-19 | 176.60 | -2.21% | 4,901 |
23-09-18 | 180.60 | -0.33% | 3,590 |
Delayed Quote Swiss Exchange, September 22, 2023 at 11:30 am EDT
More quotes
HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.
Calendar
2023-10-19
- Q2 2024 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
D+
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
175.40CHF
Average target price
236.00CHF
Spread / Average Target
+34.55%
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. (M$) | |
---|---|---|
-12.74% | 1 346 M $ | |
-23.98% | 1 233 M $ | |
+9.03% | 580 M $ | |
+4.13% | 437 M $ | |
-35.74% | 424 M $ | |
+49.59% | 422 M $ | |
-1.83% | 250 M $ | |
-12.70% | 244 M $ | |
+24.28% | 2 452 M $ | |
+6.00% | 236 M $ |